Page last updated: 2024-08-24

gemcitabine and Bile Duct Cancer

gemcitabine has been researched along with Bile Duct Cancer in 327 studies

Research

Studies (327)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (0.61)	18.2507
2000's	49 (14.98)	29.6817
2010's	178 (54.43)	24.3611
2020's	98 (29.97)	2.80

Authors

Authors	Studies
Belkouz, A; Besselink, MG; Busch, OR; Erdmann, JI; Franken, LC; Klümpen, HJ; Nooijen, LE; Oulad Abdennabi, I; Swijnenburg, RJ	1
Ebata, T; Mizuno, T; Takahashi, D	1
Mungmungpuntipantip, R; Wiwanitkit, V	1
Wu, CE; Yeh, CN	1
Deng, L; Gao, Y; Gu, Y; Han, S; Li, X; Li, Z; Wang, D; Wang, X; Yang, R; Yin, A; Yu, Y	1
Endo, I; Hiratani, S; Homma, Y; Kumamoto, T; Matsuyama, R; Miyake, K; Mori, R; Murakami, T; Ota, Y; Sawada, Y; Shimizu, Y; Yabusita, Y	1
Cox, V; Javle, M; Kang, HC; Kawaguchi, Y; Kim, BJ; Maki, H; Mizuno, T; Panettieri, E; Pant, S; Vauthey, JN; Vega, EA	1
Hwang, JH; Jung, JH; Jung, K; Kim, J; Lee, JC; Park, J	1
Bartels, A; Bolch, M; Branchi, V; Dold, L; Gonzalez-Carmona, MA; Heling, DJ; Kaczmarek, DJ; Kalff, JC; Mahn, R; Manekeller, S; Matthaei, H; Mohr, RU; Möhring, C; Nattermann, J; Sadeghlar, F; Strassburg, CP; Vogt, A; Weismüller, TJ; Zhou, T	1
Ambo, Y; Ando, M; Benabdelghani, M; Bertaut, A; Ebata, T; Edeline, J; Hammel, P; Hirano, S; Joly, JP; Kaneoka, Y; Konishi, M; Louvet, C; Malka, D; Monard, L; Nagino, M; Ohtsuka, M; Phelip, JM; Uesaka, K; Watelet, J; Yamamoto, M	1
Jaidee, R; Jusakul, A; Kongpetch, S; Kukongviriyapan, V; Laphanuwat, P; Prawan, A; Senggunprai, L	1
Jarearnrat, A; Khuntikeo, N; Klanrit, P; Li, JV; Loilome, W; Mahalapbutr, P; Namwat, N; Phetcharaburanin, J; Sa-Ngiamwibool, P; Suksawat, M; Techasen, A; Titapun, A; Vilayhong, V; Wangwiwatsin, A	1
Bhosale, P; Danner De Armas, A; Javle, M; Lee, S; Makawita, S; Pant, S; Raghav, K; Reddy, K; Shalaby, A; Shroff, RT; Wolff, RA; Xiao, L	1
Bran, DM; Fuks, D; Gallois, C; Karoui, M; Lahlou, W; Lansier, A; Taieb, J	1
Chiawpanit, C; Chieochansin, T; Junking, M; Lee, VS; Luangwattananun, P; Nimmanpipug, P; Panya, A; Phanthaphol, N; Rotarayanont, S; Sangsuwannukul, T; Sawasdee, N; Somboonpatarakun, C; Sujjitjoon, J; Tragoolpua, Y; Wathikthinnakon, M; Wutti-In, Y; Yenchitsomanus, PT	1
Arasawa, S; Fukunaga, T; Goda, K; Hoshi, S; Hoshi, T; Inamoto, O; Kajimura, K; Miyajima, S; Takaya, H; Takeda, S; Tanaka, Y	1
Ibusuki, M; Inoue, T; Ito, K; Kitano, R; Kobayashi, Y; Naitoh, I; Nakade, Y; Sumida, Y; Yoneda, M	1
Ishii, M; Itano, O; Itano, S; Morinaga, J; Shirakawa, H	1
Detarya, M; Hino, S; Koga, T; Nakao, M; Saengboonmee, C; Seubwai, W; Thamrongwaranggoon, U; Wongkham, S	1
Abdelrahim, M; Abudayyeh, A; Al Najjar, E; Al-Rawi, H; Al-Rawi, M; Bugazia, D; Esmail, A; Ghobrial, RM; Ibnshamsah, F; McMillan, R; Saharia, A; Umoru, G; Victor, D; Xu, J	1
Crocenzi, TS; Driscoll, M; Hansen, P; Kelly, LR; Martin, RCG; McMasters, KM; Philips, P; Rocha, F; Scoggins, CR; Sharma, VR; Simo, KA; Tatum, CM	1
Dechêne, A; Finnesand, L; Hoffmeister, A; Høgset, A; Jakobs, R; Jürgensen, C; Kasper, S; Neu, B; Olivecrona, H; Palmer, D; Schirra, J; Selbo, PK; Sturgess, R; Trojan, J; Walday, P	1
Bai, LY; Chao, Y; Chen, LT; Chen, MH; Chen, SC; Chen, SJ; Chiang, NJ; Hsiao, CF; Huang, CJ; Huang, CY; Huang, YH; Hung, YP; Lee, IC; Lee, PC; Shan, YS; Su, YY; Tan, KT; Yeh, CN	1
Chen, E; DeLuca, S; Dhani, N; Doherty, MK; Hedley, D; Jang, R; Knox, JJ; McNamara, MG; O'Kane, GM; Pedutem, T; Sim, HW; Tam, VC; Tang, P; Wang, L	1
Beg, MS; Deming, DA; Griffith, KA; Mahalingam, D; Sahai, V; Shaib, WL; Zalupski, MM; Zhen, DB	1
Chen, X; Li, Y; Qian, Y; Qiao, L; Shi, C; Tang, L; Wu, D; Xie, F; Yang, C; Yang, J; Zheng, Y	1
Jarearnrat, A; Khuntikeo, N; Klanrit, P; Loilome, W; Namwat, N; Phetcharaburanin, J; Sangkhamanon, S; Sitthirak, S; Suksawat, M; Titapun, A; Wangwiwatsin, A	1
Ahn, D; Bai, LY; Bayat, A; Borad, MJ; Davis, SL; Hubbard, J; McCormick, D; Mody, K; O'Brien, D; Oh, DY; Park, JO; Rha, SY; Richards, D; Soong, J; Tse, E	1
Arihiro, K; Ishii, Y; Okada, K; Otsuka, H; Serikawa, M; Shintakuya, R; Sumiyoshi, T; Takahashi, S; Tsuboi, T; Uemura, K	1
Kuraoka, K; Onoe, T; Shibata, Y; Shimizu, Y; Sudo, T; Suzuki, T; Takahashi, S; Tashiro, H; Tazawa, H; Tazuma, S	1
Cheon, J; Choi, SH; Chon, HJ; Kang, B; Kang, I; Kim, DJ; Kim, G; Ko, KH; Kwon, CI; Lee, SH	1
Ahmed, O; Baker, T; Fung, J; Hwang, G; Liao, CY; Patel, M; Pillai, A; Yu, Q	1
Ding, DY; Ding, WB; Gan, XJ; Hou, GJ; Li, W; Liu, L; Sun, DP; Tao, QF; Yang, F; Yang, Y; Yu, J; Yuan, SX; Zhang, JN; Zhou, WP	1
Fan, J; Gan, Y; Han, Y; Li, B; Peng, F; Rao, M; Su, S; Tang, H; Wang, R; Yang, X; Zhang, J; Zhang, X	1
Albers, D; Herold, T; Kasper, S; Linden, G; Markus, P; Prasnikar, N; Radunz, S; Schmidt, H; Schuler, M; Schumacher, B; Siveke, J; Ting, S; Treckmann, JW; Virchow, I; Wiesweg, M	1
Baba, H; Eguchi, H; Hatano, E; Ioka, T; Kamachi, H; Kanai, M; Kobayashi, S; Nagano, H; Nakagami, Y; Sakai, D; Shindo, Y; Takahashi, M; Takayama, T; Ueno, M; Wada, H; Yoshimura, K	1
Chai, C; Hu, J; Luo, W; Miao, X; Tang, H; Xu, H; Zhang, H; Zhao, Z; Zhou, W	1
Chen, XP; Luo, C; Zhang, BX; Zhang, W; Zhang, ZY	1
Funakoshi, S; Harada, H; Hayashi, T; Hirose, S; Hoshino, M; Odaira, M; Ogura, N	1
Aoyama, S; Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kihara, Y; Kinoshita, M; Masuzawa, T; Muneta, M; Murata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y	1
Bramwell, LG; Cheung, K; Falchook, GS; Janku, F; Javle, MM; Johansen, MJ; Madden, T; Maier, G; Pant, S; Saeki, K; Sen, S; Subach, RA; Subbiah, V; Suzuki, T; Wages, DS; Way, T; Wheeler, CA	1
Akahane, T; Iwai, S; Kaji, K; Kitagawa, K; Kubo, T; Mitoro, A; Namisaki, T; Nishimura, N; Shibamoto, A; Suzuki, J; Tomooka, F; Yoshiji, H	1
Chen, DS; Chen, XY; Cheng, Z; Deng, WL; Dong, YL; Guo, LP; Han, Q; Lou, C; Qi, C; Shang, PP; Song, YJ; Tao, CJ; Wei, W; Xu, HM; Yang, G; Yuan, ZG; Zeng, TM	1
Abadi, S; Davies, JM; Ho, C; Mathers, B; McIntyre, C	1
Chon, HJ; Hwang, DW; Jeong, H; Jeong, JH; Kim, KH; Kim, KP; Lee, JH; Lee, JS; Lee, MA; Moon, DB; Park, JH; Park, SJ; Ryoo, BY; Yoo, C	1
Achreja, A; Animasahun, O; Chinnaiyan, AM; Choppara, S; Crysler, O; Dippman, D; Enzler, T; Griffith, KA; Gunchick, V; Hsiehchen, D; Kumar-Sinha, C; Mohan, A; Nagrath, D; Nenwani, M; Sahai, V; Wuchu, F; Zalupski, MM; Zhen, DB	1
Cheng, SQ; Cheng, YQ; Feng, S; Guo, WX; Ni, QZ; Shi, J; Wang, K; Xiang, YJ; Yu, HM; Zhai, J	1
Chen, J; Wang, T; Yu, X; Zhu, L	1
Cheon, J; Choi, HJ; Choi, SH; Chon, HJ; Jung, S; Kang, B; Kim, C; Lee, CK; Lee, S; Lee, SH; Park, YN; Shim, HS	1
Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A	1
Bao, L; Bao, Y; Boyken, L; Bridgewater, J; Chang, HM; Chen, EY; Choi, HJ; Ducreux, M; Fan, J; Garfin, P; Harding, JJ; Kim, DU; Kim, JW; Lee, MA; Ma, J; Macarulla, T; Metges, JP; Oh, DY; Pant, S; Sun, HC; Tejani, MA; Wasan, H; Xie, F; Ying, J	1
Chang, YC; Chen, MH; Chou, WC; Huang, SC; Huang, WK; Hung, TH; Jung, SM; Lin, SH; Pan, YR; Wu, CE; Yeh, CN; Yu, AL	1
Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ	1
Cui, XW; Dong, LW; Feng, XF; Jiang, TY; Lin, YK; Pan, YF; Tan, YX; Wang, HY; Yuan, ZG; Zeng, TM	1
Aldrighetti, L; Angotti, L; Antonuzzo, L; Caliman, E; Casadei-Gardini, A; Cascinu, S; Cerantola, R; Cornara, N; Daniele, B; Diana, A; Formica, V; Fornaro, L; Garajová, I; Giordano, G; Gusmaroli, E; Landriscina, M; Lavacchi, D; Lonardi, S; Lucchetti, J; Martinelli, E; Nichetti, F; Niger, M; Pastorino, A; Persano, M; Pirrone, C; Pressiani, T; Pretta, A; Ramundo, M; Rapposelli, IG; Ratti, F; Rimassa, L; Rimini, M; Rizzato, MD; Salani, F; Scartozzi, M; Schirripa, M; Simionato, F; Tamburini, E; Vivaldi, C; Zanuso, V	1
Gu, HF; Hu, YF; Jin, YW; Li, FY	1
Jeong, H; Yoo, C	1
Guo, J; He, H; Hu, Y; Jin, S; Li, X; Zhang, H; Zhang, J	1
Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Miyashiro, I; Morishima, T; Mukai, K; Nakabori, T; Ohkawa, K; Seiki, Y; Takada, R; Uehara, H; Urabe, M; Watsuji, K; Yamai, T	1
Hong, JY; Kim, ST; Lim, SH; Park, JO; Park, YS	1
Chen, J; Li, H; Lin, H; Sun, H; Wang, X; Zhang, Z	1
Avallone, A; Bouattour, M; Burris, H; Chen, JS; Chen, LT; Cohen, G; Cundom, J; He, AR; Ikeda, M; Kim, JW; Kitano, M; Kurland, JF; Lee, CK; Lee, MA; Makowsky, M; McNamara, MG; Oh, DY; Okusaka, T; Qin, S; Rokutanda, N; Suksombooncharoen, T; Takahashi, H; Tan, B; Tanasanvimon, S; Valle, JW; Vogel, A; Wang, J; Zaucha, R; Żotkiewicz, M	1
Detarya, M; Janeklang, S; Kidoikhammouan, S; Mahalapbutr, P; Pabuprapap, W; Saengboonmee, C; Sawanyawisuth, K; Seubwai, W; Suksamrarn, A; Thothaisong, T; Vaeteewoottacharn, K; Waenphimai, O; Wongkham, S	1
Balachandran, VP; Cercek, A; D'Angelica, MI; Drebin, JA; Franssen, S; Groot Koerkamp, B; Harding, JJ; Holster, JJ; Homs, MYV; Jarnagin, WR; Jolissaint, JS; Kemeny, NE; Kingham, TP; Klümpen, HJ; Mostert, B; Nooijen, LE; Soares, KC; Swijnenburg, RJ; Wei, AC	1
Fung, S; Syed, YY	1
Choodetwattana, P; Jearanaikoon, P; Limpaiboon, T; Proungvitaya, S	1
Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM	1
Junking, M; Panya, A; Poungvarin, N; Sawasdee, N; Sujjitjoon, J; Thepmalee, C; Yenchitsomanus, PT; Yongpitakwattana, P	1
Choe, JW; Kim, HJ; Kim, JS	1
Aravantinos, G; Demiri, S; Fountzilas, G; Koliou, GA; Lampropoulou, DI; Pectasides, D; Pentheroudakis, G; Psyrri, A; Razis, E; Samantas, E; Sgouros, J; Zagouri, F	1
Calvisi, DF; Chen, X; Cigliano, A; Dituri, F; Giannelli, G; Mancarella, S; Ribback, S; Serino, G; Wang, J	1
Hwang, JH; Kim, J; Kim, MJ; Lee, JC; Lee, KH; Lee, WJ; Shin, DW; Woo, SM	1
Egawa, C; Haruna, K; Hata, T; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A; Yanagawa, T; Yanai, A	1
Pan, J; Yang, X; Zhao, H	1
Cercek, A; Jarnagin, WR	1
Heneghan, M; Kitagawa, M; Prachalias, A; Srinivasan, P; Suzuki, K; Zen, Y	1
André, T; Bekaii-Saab, T; Bridgewater, J; Cunningham, D; Goldstein, D; Jensen, LH; Knox, JJ; Koeberle, D; Lopes, A; Malka, D; McNamara, MG; Moehler, M; Okusaka, T; Shannon, J; Valle, JW; Wagner, AD; Wasan, H	1
Borbath, I; Delaunoit, T; Demols, A; Goemine, JC; Holbrechts, S; Houbiers, G; Laurent, S; Marechal, R; Paesmans, M; Peeters, M; Van den Eynde, M; Van Laethem, JL	1
Abdul-Rahim, O; Khushman, M; Phung, T; Surinach, A	1
Hsiao, CY; Huang, KW; Li, X; Yang, PC	1
Albino, V; Granata, V; Izzo, F; Palaia, R; Petrillo, A; Piccirillo, M; Venanzio Setola, S	1
Deng, GL; Hu, YY; Wan, XJ; Weng, JY; Xiao, JB	1
Bardia, A; Elhence, PA; Nag, P; Pareek, P	1
Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK	1
Furuse, J; Hosoi, H; Ikeda, M; Kobayashi, S; Maeno, S; Morimoto, M; Morizane, C; Nagashima, F; Nakai, Y; Ojima, H; Okano, N; Okusaka, T; Ozaka, M; Sasaki, M; Takahara, N; Ueno, M; Yamanaka, T	1
Akahane, T; Kaji, K; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Nishimura, N; Saikawa, S; Sato, S; Yoshiji, H	1
Belkouz, A; Erdmann, JI; Franken, LC; Klümpen, HJ; Nooijen, LE; Punt, CJA; Riady, H; van Oijen, MGH	1
Bezrookove, V; Dar, AA; de Semir, D; Ice, RJ; Kashani-Sabet, M; McAllister, S; Nosrati, M; Osorio, R; Proetsch-Gugerbauer, H; Saqub, H; Soroceanu, L; Vaquero, EM	1
Anjarwalla, S; Lakshmaiah, S; Marzouk, O	1
Geng, X; Li, G; Liu, Z; Lu, M; Qin, X; Yue, H; Zhou, Y	1
Akhoundova, D; Bachmann, H; Breitenstein, S; Clavien, PA; Knuth, A; Nguyen-Kim, TDL; Pestalozzi, B; Petrowsky, H; Pietge, H; Samaras, P; Sánchez-Velázquez, P; Siebenhüner, A; Winder, T	1
Billingsley, KG; Dewey, EN; Enestvedt, CK; Mayo, SC; Orloff, SL; Sutton, TL; Walker, BS	1
Becker, D; Kendre, G; Kühnel, F; Lorz, G; Marhenke, S; Marquardt, JU; Murugesan, K; Pich, A; Poth, T; Reineke-Plaaß, T; Saborowski, A; Saborowski, M; Vogel, A; Wirtz, RM; Woller, N	1
Byeon, S; Hong, JY; Jang, KT; Kang, WK; Kim, H; Kim, J; Kim, ST; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS	1
Chen, G; Deng, T; Ding, X; Li, J; Wang, Y; Wu, L; Xie, X; Yang, Z; Ye, L; Yu, H; Yu, Z; Zheng, Y; Zhu, Q	1
Ando, M; Ebata, T; Igami, T; Maeda, O; Mizuno, T; Onoe, S; Takahashi, D; Watanabe, N; Yamaguchi, J; Yokoyama, Y	1
Bian, W; Liu, JH; Liu, SG; Lv, HT; Wang, WB; Xing, L; Zhang, TF	1
Adachi, T; Doi, S; Katsukura, N; Kikuchi, K; Kikuyama, T; Matsui, K; Matsumoto, K; Namura, Y; Okamoto, K; Saito, G; Tsujikawa, T; Tsunashima, H; Watanabe, A	1
Cavaletti, G; Celio, L; Damian, S; Malacrida, A; Mazzaferro, V; Miloso, M; Rigolio, R	1
Fischer, M; Kirstein, MM; Kratzel, AM; Lehner, F; Manns, MP; Reineke-Plaaß, T; Schweitzer, N; Vogel, A; Weber, T	1
Andersen, JB; Burmeister, K; Fusco, A; Karamitopoulou, E; Matter, MS; Pallante, P; Piscuoglio, S; Quagliata, L; Quintavalle, C; Sepe, R; Terracciano, LM	1
Asai, A; Asaoka, T; Asukai, K; Doki, Y; Eguchi, H; Gotoh, K; Ishii, H; Iwagami, Y; Kawamoto, K; Konno, M; Mori, M; Nishida, N; Noda, T; Satoh, T; Wada, H; Yamada, D	1
Aldrighetti, L; Alexandrescu, S; Bagante, F; Bauer, TW; Ejaz, A; Guglielmi, A; Itaru, E; Koerkamp, BG; Maithel, SK; Marques, HP; Martel, G; Pawlik, TM; Poultsides, GA; Pulitano, C; Reames, BN; Ruzzenente, A; Shen, F; Soubrane, O; Spolverato, G; Weiss, M	1
Bansal, P; Baron, AD; Bedrick, E; Boumber, Y; Du, R; Fekrazad, MH; Lee, FC; Lee, SJ; Murad, W; Patt, YZ; Steinberg, K	1
Bianco, C; Bianco, R; Marciano, R; Servetto, A	1
Ishimoto, U; Kondo, S; Morizane, C; Ohba, A; Okusaka, T; Sakamoto, Y; Sasaki, M; Ueno, H	1
Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S	1
Buckstein, M; Ghiassi-Nejad, Z; Moshier, E; Ru, M; Schwartz, M; Tabrizian, P; Tarchi, P	1
Bruckner, HW; Gurell, D; Hirschfeld, A	1
Baiu, I; Charville, GW; Visser, BC	1
Aglietta, M; Aprile, G; Avallone, A; Cagnazzo, C; Cavalloni, G; Cereda, S; Doglioni, C; Fenocchio, E; Frattini, M; Gammaitoni, L; Leone, F; Martin, V; Nasti, G; Peraldo-Neia, C; Reni, M; Satolli, MA; Spadi, R; Venesio, T	1
Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H	1
Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Mitsuhashi, Y; Toyoki, Y; Wakiya, T; Yakoshi, Y	1
Ambo, Y; Ando, M; Ebata, T; Fukutomi, A; Hirano, S; Kaneoka, Y; Konishi, M; Nagino, M; Nimura, Y; Ohtsuka, M; Ozawa, F; Shimizu, Y; Tsuchiya, Y; Uesaka, K; Yamamoto, M	1
Brade, A; Dawson, LA; Gallinger, S; Greig, PD; Horgan, AM; Knox, JJ; Loveday, BPT; Metser, U; Moulton, CA	1
Kondo, N; Murakami, Y; Nakagawa, N; Sueda, T; Takahashi, S; Toyota, K; Uemura, K	1
Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K	1
Brezault, C; Coriat, R; Guillaumot, MA; Léandri, C; Ribiere, SC	1
Einama, T; Kamachi, H; Kamiyama, T; Nagatsu, A; Ohmura, T; Orimo, T; Shimada, S; Sugiyama, K; Taketomi, A; Wakayama, K; Yokoo, H	1
Izumiya, Y; Kawakami, S; Kimura, Y; Kin, S; Komiyama, S; Nakashima, S	1
Kawabe, K; Kawamoto, M; Koya, N; Morisaki, T; Nakagawa, S; Nakamura, M; Onishi, H; Tanaka, H; Umebayashi, M	1
Chae, H; Chang, HM; Cho, H; Hwang, S; Jeong, JH; Kang, J; Kim, KM; Kim, KP; Lee, HC; Lee, JH; Lee, SS; Lee, YJ; Lim, YS; Moon, DB; Park, DH; Ryoo, BY; Shim, JH; Song, GW; Song, TJ; Yoo, C	1
Kim, HO; Lee, SR; Shin, JH	1
Hwang, HS; Im, BN; Kim, DH; Na, K	1
Benson, AB; Catalano, PJ; Lubner, SJ; Menge, MR; Munshi, HG; Nimeiri, HS; O'Dwyer, PJ; Sahai, V; Zalupski, MM	1
Eskens, FALM; Groot Koerkamp, B; Heijmen, BJM; Koedijk, MS; Méndez Romero, A; Poley, JW; Sprengers, D; van der Holt, B; van der Laan, LJW; van Gent, DC; Willemssen, FEJA	1
Rao, M; Soni, SC; Sureka, B; Varshney, VK	1
Bergeat, D; Coulouarn, C; De La Torre, C; Dooley, S; Ebert, MPA; Gretz, N; Li, J; Liebe, R; Lin, T; Sulpice, L; Weng, HL; Yuan, X	1
Barbier, E; Blanc, JF; Bourgeois, V; Desrame, J; Edeline, J; Malka, D; Manfredi, S; Michel, P; Neuzillet, C; Phelip, JM	1
Bolch, M; Branchi, V; Gonzalez-Carmona, MA; Jansen, C; Kalff, JC; Mahn, R; Manekeller, S; Matthaei, H; Mohr, RU; Nattermann, J; Praktiknjo, M; Sampels, M; Strassburg, CP; Trebicka, J; van Beekum, K; Vogt, A; Weismüller, TJ	1
Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Yachi, T	1
Bai, J; Cheng, Y; Li, H; Meng, F; Shi, G; Wang, C; Xu, S; Ye, H; Zhang, L; Zhang, P; Zhang, Z; Zhong, L	1
Adeva, J; Berardi, R; Bittoni, A; Bruix, J; Edeline, J; La Casta, A; Salati, M; Sangro, B; Valle, JW	1
Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Hatano, E; Higashiguchi, M; Ioka, T; Iwagami, Y; Kobayashi, S; Mori, M; Noda, T; Sakai, D; Yamada, D	1
Hata, T; Imamoto, H; Kawada, J; Kim, Y; Miwa, H; Murakami, M; Okano, M; Okuyama, M; Shimizu, J; Tanizaki, K; Tsujinaka, T; Yamasaki, M	1
Adachi, K; Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Kumamoto, Y; Miyata, E; Nishiyama, R; Okuwaki, K; Yamauchi, H	1
Fukumitsu, K; Ishii, T; Kaido, T; Morino, K; Nishino, H; Okajima, H; Seo, S; Taura, K; Uemoto, S; Yamanaka, K; Yoh, T	1
Ahn, DH; Bekaii-Saab, TS; Borad, MJ; Iwasaki, M; Javle, MM; Kaseb, AO; Masci, P; Raghav, KPS; Ramanathan, RK; Shroff, RT; Varadhachary, GR; Wolff, RA; Xiao, L	1
Kim, HS; Kim, K; Lee, JK; Lee, KH; Lee, KT; Park, JK; Song, BG	1
Autorino, R; Bisello, S; Brandi, G; Buwenge, M; Cammelli, S; Cellini, F; Cilla, S; Deodato, F; Macchia, G; Mattiucci, GC; Morganti, AG; Palloni, A; Tagliaferri, L; Valentini, V	1
Ahn, KS; Allotey, LK; Borad, MJ; Kang, KJ; Kang, YN; Kim, TS; Kim, YH; Kocher, JA; Mounajjed, T; O'Brien, D; Roberts, LR	1
Ayaki, M; Horie, S; Kashiwagi, R; Mitsuda, A; Tanaka, H	1
Ajiki, T; Fukumoto, T; Ku, Y; Matsumoto, I; Murakami, S; Okazaki, T; Otsubo, I; Sawa, H; Shinozaki, K; Tsuchida, S; Ueno, K; Yoshida, Y	1
Armbrecht, N; Fleischmann-Mundt, B; Gürlevik, E; Hoffmann, D; Kloos, A; Kubicka, S; Kühnel, F; Longerich, T; Manns, MP; Schambach, A; Wirth, TC; Woller, N; Zender, L	1
Akiba, J; Arinaga-Hino, T; Kage, M; Kawaguchi, T; Nakashima, O; Niizeki, T; Sata, M; Takenaka, M; Yano, H	1
Chauffert, B; Ghiringhelli, F; Wiazzane, N	1
Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K	1
Chindaprasirt, J; Khuntikeo, N; Ngamprasertchai, T; Pakkhem, A; Sookprasert, A; Ungarereevittaya, P; Wirasorn, K	1
Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU	1
Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH	1
Borbath, I; Ceratti, A; Delaunoit, T; Deleporte, A; Demols, A; Laurent, S; Sempoux, C; Van Cutsem, E; Van Laethem, JL; Van Maanen, A; Vergauwe, P; Verslype, C	1
Carberry, M; Damjanov, N; Giantonio, BJ; Jacobs-Small, M; Mykulowycz, K; O'Dwyer, PJ; Sepulveda, A; Sohal, DP; Sun, W; Teitelbaum, UR; Uehara, T; Wissel, P	1
Miyoshi, K; Murawaki, Y; Okamoto, K	1
Kondo, T; Ohkohchi, N; Oshiro, Y; Sakashita, S; Sasaki, R; Takahashi, K	1
Baba, H; Beppu, T; Hashimoto, D; Hayashi, H; Kuroki, H; Mima, K; Nakagawa, S; Okabe, H; Sakamoto, K; Sakamoto, Y; Tokunaga, R; Yokoyama, N	1
Beare, S; Bridgewater, J; Furuse, J; Jitlal, M; Mizuno, N; Okusaka, T; Valle, JW; Wasan, H	1
Fukushima, Y; Hashimoto, K; Ide, Y; Kodama, K; Matsuyama, J; Morimoto, T; Nomura, T; Sasaki, Y; Takeda, M; Tokuoka, M; Toshiyama, R; Yokoyama, S	1
Kukongviriyapan, V; Prawan, A; Senggunprai, L; Sripa, B; Zeekpudsa, P	1
Goldberg, SN	1
Kolokythas, O; Le, T; Meng, Y; Soriano, SS; Wang, H; Wei, B; Willis, P; Wu, X; Yang, X; Zhang, F; Zhang, T	1
Aoyama, F; Hiyoshi, M; Kataoka, H; Sawaguchi, A; Takahashi, N	1
Furukawa, H; Furuse, J; Ojima, H; Shibata, T; Shimizu, H; Takahashi, H	1
Ghiringhelli, F; Guiu, B; Ladoire, S; Lorgis, V; Vincent, J	1
Cheon, YK; Hong, MJ; Lee, EJ; Lee, TY; Shim, CS	1
André, T; Assenat, E; Blanc, JF; Boucher, E; Cervera, P; de la Fouchardière, C; Dollinger, M; Ducreux, M; Faivre, S; Fartoux, L; Foulon, S; Grenier, J; Greten, TF; Hahn, P; Hammel, P; Heinemann, V; Herrmann, T; Malka, D; Pignon, JP; Rosmorduc, O; Rousseau, V; Seufferlein, T; Trarbach, T; Viret, F; Wendum, D	1
Akiyama, N; Akiyoshi, K; Fujioka, K; Funamizu, N; Ikeda, K; Kamada, M; Manome, Y; Watanabe, M	1
Hoegdall, DT; Jensen, LH; Larsen, FO; Mellergaard, AH	1
Hashimoto, Y; Kondo, N; Murakami, Y; Sasaki, H; Sudo, T; Sueda, T; Uemura, K	1
Arakawa, H; Gong, J; Hayashi, K; Homma, S; Ikegami, M; Imazu, H; Ishidao, T; Ito, M; Kajihara, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Koyama, S; Misawa, T; Mori, M; Odahara, S; Ohkusa, T; Okamoto, M; Shimodaira, S; Sugiyama, H; Tajiri, H; Takakura, K; Toyama, Y; Tsukinaga, S; Uchiyama, K; Yanagisawa, S; Yoshizaki, S; Yusa, S	1
Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X	1
Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S	1
Grąt, M; Kornasiewicz, O; Krasnodębski, M; Krawczyk, M; Patkowski, W; Stankiewicz, R	1
Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S	1
Bae, KS; Cho, JM; Choi, HJ; Go, SI; Kang, MH; Kim, DC; Kim, HG; Kim, MJ; Lee, JH; Lee, US; Lee, WS	1
Wang, JF; Wu, DP; Ye, WL	1
Kukongviriyapan, V; Prawan, A; Samatiwat, P; Senggunprai, L	1
Aoki, Y; Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Miyazaki, M; Ohtsuka, M; Okamura, D; Sakai, N; Shimizu, H; Suzuki, D; Suzuki, T; Takano, S; Takayashiki, T; Yoshitomi, H	1
Katayose, Y; Morikawa, T; Otsuka, H; Shirasaki, K; Unno, M	1
Ajiki, T; Fukumoto, T; Ku, Y; Matsumoto, I; Matsumoto, T; Murakami, S; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y	1
Fujie, Y; Fujita, J; Fujita, S; Hashimoto, K; Imaoka, S; Monden, T; Nishida, K; Nonaka, R; Ohnishi, T; Tono, T; Tsunashima, R; Yoshida, T	1
Araki, H; Choda, Y; Harano, M; Idani, H; Kanazawa, T; Kato, T; Matsukawa, H; Mimura, N; Miyake, S; Miyoshi, H; Ninomiya, M; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Taguchi, K; Takahashi, K; Tokumoto, N; Toshima, T; Yamaguchi, K; Yoshida, K	1
Ishii, H; Osumi, H; Ozaka, M; Sasahira, N	1
Bal, CK; Chatrath, BS; Longacre, TA; Poultsides, GA; Schaberg, K; Tran, TB	1
Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM	1
Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W	1
Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K	1
Diniz, AL; Forsmark, CE; Zhu, AX	1
Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Paik, WH; Ryu, JK; Son, JH	1
Arnold, D; Bridgewater, J; Goldstein, D; Jensen, LH; Klümpen, HJ; Lohse, AW; Nashan, B; Primrose, J; Schrum, S; Shannon, J; Stein, A; Vettorazzi, E; Wege, H	1
Asano, T; Cho, A; Furukawa, D; Kainuma, O; Miura, F; Nakagohri, T; Sano, K; Yamamoto, H	1
Fujimori, T; Fujita, K; Fujiwara, S; Iwama, H; Kamada, H; Kato, K; Katsura, A; Kobayashi, K; Masaki, T; Mimura, S; Miyata, M; Miyoshi, H; Morishita, A; Nomura, T; Okano, K; Okura, R; Sakamoto, T; Suzuki, Y; Tadokoro, T; Tani, J; Toyota, Y; Yoneyama, H	1
Bassi, N; Brivio, S; Cadamuro, M; Fabris, L; Floreani, A; Furlanetto, A; Joplin, RE; Massani, M; Morton, SD; Stecca, T; Strazzabosco, M; Vismara, M	1
Aglietta, M; Amatu, A; Aprile, G; Belli, C; Cagnazzo, C; Cereda, S; Ciuffreda, L; Fasola, G; Filippi, R; Leone, F; Marino, D; Montano, M; Nasti, G; Reni, M; Siena, S; Spadi, R	1
Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R	1
Furukawa, H; Kofunato, Y; Koyama, Y; Kumamoto, K; Shimura, T; Takenoshita, S; Yashima, R	1
Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Groot Koerkamp, B; Jarnagin, WR; Kemeny, NE; Kingham, TP; Klimstra, DS; Konstantinidis, IT	1
Asano, T; Kanomata, H; Matsuoka, Y; Miyamoto, Y; Murayama, M; Seyama, Y; Takahashi, M; Tani, K; Tanizawa, T; Umekita, N; Warabi, M	1
Abe, T; Aoki, S; Hayashi, H; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, R; Okada, Y; Oyauchi, M; Sakata, N; Unno, M; Yoshida, H	1
Büning, C; Jürgensen, C; Mitroshkin, A; Prager, M; Schachschal, G; Voderholzer, W; Wentrup, R; Winkelmann, N	1
Ardito, F; Autorino, R; Balducci, M; Deodato, F; Gambacorta, MA; Giuliante, F; Macchia, G; Mantini, G; Mattiucci, GC; Morganti, AG; Perri, V; Tagliaferri, L; Tringali, A; Valentini, V	1
Chen, X; Duan, X; He, J; He, K; Huang, R; Xia, Z; Xiang, G; Xiao, J; Zhang, J; Zhou, W	1
Chio-Srichan, S; Hahnvajanawong, C; Heraud, P; Jearanaikoon, P; Leelayuwat, C; Limpaiboon, T; Tippayawat, P; Wongwattanakul, M	1
Augustyn, M; Grys, I; Iwaniec-Karlikowska, E	1
Barbera, MA; Biasco, G; Brandi, G; Cescon, M; Cucchetti, A; D'Errico-Grigioni, A; de Lorenzo, S; Degiovanni, A; Deserti, M; Di Marco, M; Ercolani, G; Farioli, A; Frega, G; Garajova, I; Palloni, A; Pantaleo, MA; Pinna, AD; Tavolari, S; Vasuri, F	1
Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z	1
Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ	1
Endlicher, E; Gelbmann, C; Klebl, F; Kullmann, F; Messmann, H; Rogler, G; Schnoy, E; Troppmann, M	1
Chan-On, W; Huyen, NT; Prachayasittikul, V	1
Ebata, T; Igami, T; Mizuno, T; Nagino, M; Sugawara, G; Yamaguchi, J; Yokoyama, Y	1
Fujibayashi, S; Fujiya, M; Goto, T; Kawamoto, T; Kohgo, Y; Koizumi, K; Moriichi, K; Sasajima, J; Sugiyama, Y; Yamada, M	1
Chen, J; Cui, Y; Han, J; Jing, H; Sha, D; Wang, C; Wang, W	1
Fukuda, S; Kuga, Y; Moriya, T; Nishida, T	1
Aristizabal-Alzate, A; Florez-Vargas, AA; Galvez-Cárdenas, KM; Higuita, LM; Nieto-Ríos, JF; Ocampo-Kohn, C; Rincón, CI; Zuluaga-Quintero, M; Zuluaga-Valencia, GA	1
Iida, T; Kaneto, H; Kon, S; Konishi, Y; Murakami, K; Sasaki, K; Satoh, S; Shimizu, H; Yamamoto, I; Yokoyama, Y	1
Chang, H; Gao, HJ; Li, HG; Liu, FF; Lu, J; Ma, CQ; Ma, JB; Song, X; Zhou, X; Zhu, HQ	1
Giovannetti, E; Kazemier, G; Meijer, LL; Peters, GJ; Puik, JR	1
Grande, C; Groman, A; Iancu, DM; Iyer, RV; Ma, WW; Malhotra, U; Pokuri, VK; Saab, TB	1
Akita, H; Fujiwara, Y; Fukui, K; Gotoh, K; Kobayashi, S; Marubashi, S; Sakon, M; Takahashi, H; Teshima, T; Tomokuni, A; Yamada, T	1
Asmann, Y; Foye, C; Maji, S; Matsuda, A; Nguyen, P; Parasramka, M; Patel, T; Wang, X; Yan, IK	1
Hanazaki, K; Kitagwa, H; Munekage, M; Namikawa, T; Sugimura, K; Takezaki, Y	1
Endo, K; Hirose, Y; Kameyama, H; Kido, T; Kobayashi, T; Miura, K; Morimoto, Y; Otani, A; Otani, T; Sakata, J; Tamura, H; Wakai, T; Yoshino, K	1
Fukumoto, K; Kobayashi, H; Koizumi, N; Nakase, Y; Takagi, T	1
Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, K; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Uemura, M; Yamamoto, K	1
Cho, S; Hong, HJ; Hwang, H; Jeong, MS; Kang, SG; Kim, AR; Kim, H; Lee, TS; Lee, YJ; Song, IH	1
Altan, B; Araki, K; Hosouchi, Y; Ishii, N; Kubo, N; Kuwano, H; Nishiyama, M; Shirabe, K; Suzuki, H; Tsukagoshi, M; Watanabe, A; Yokobori, T	1
Albrecht, T; Michalik, K; Nolte-Ernsting, C; Pereira, PL; Pützler, M; Schicho, A; Stroszczynski, C; Wiggermann, P	1
Saborowski, A; Vogel, A	1
Aizawa, M; Inose, S; Katsube, T; Kim, DH; Naritaka, Y; Ogawa, K; Shiozawa, S; Tsuchiya, A; Usui, T; Yoshimatsu, K	1
Ide, T; Kitajima, Y; Kohya, N; Mitsuno, M; Miyazaki, K; Ohtaka, K; Sato, K	1
Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY	1
Matsumoto, K; Murawaki, Y; Nagahara, T; Okano, J	1
Adamson, DJ; Ali, CW; Highley, MS; Kaye, TF; Polignano, FM; Tait, IS	1
Braconi, C; Henson, R; Lang, M; Patel, T	1
Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K	1
Pawlega, J; Zygulska, AL	1
Amatu, A; Bernardo, G; Minoia, C; Montagna, B; Poggi, G; Pozzi, E; Quaretti, P; Riccardi, A; Rossi, O; Sottani, C; Sottotetti, F; Tagliaferri, B; Villani, L; Zappoli, F	1
Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y	1
Kim, IH; Kim, SH; Kim, SW; Lee, SO	1
Hashiguchi, K; Kitahara, K; Kohya, N; Miyazaki, K; Miyoshi, A; Ohtsuka, T; Yakabe, T	1
Miura, T; Nakamura, J; Ozeki, Y; Sato, K; Suzuki, N; Takahashi, T; Yamada, S; Yanagi, M	1
Abe, K; Kanno, Y; Katsushima, F; Monoe, K; Ohira, H; Takahashi, A; Wakatsuki, T; Yokokawa, J	1
Behl, S; Behrens, R; Buechner-Steudel, P; Fahlke, J; Fleig, WE; Kleber, G; Kuss, O; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A	1
Ikeda, K; Iwata, K; Kobayashi, N; Kurihara, E; Nakamura, T; Okusawa, S; Sagae, S; Saito, J	1
Katayose, Y; Nakagawa, K; Okaue, A; Rikiyama, T; Unno, M	1
Gerhardt, T; Heller, J; Höblinger, A; Rings, D; Sauerbruch, T; Schepke, M	1
Esaki, M; Hiraoka, N; Hirohashi, S; Ino, Y; Kanai, Y; Kokubu, A; Kondo, T; Kosuge, T; Miyamoto, M; Morofuji, N; Nara, S; Ojima, H; Okusaka, T; Onaya, H; Sakamoto, Y; Shibata, T; Shimada, K; Shimizu, H; Yoshikawa, D	1
Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS	1
Anai, H; Arai, Y; Aramaki, T; Ikeda, M; Inaba, Y; Kumada, T; Najima, M; Sato, Y; Sone, M; Tanigawa, N; Yamaura, H; Yoshioka, T	1
Hamaguchi, M; Ito, S; Kokuryo, T; Nagino, M; Senga, T; Takayama, Y; Yokoyama, Y	1
Chen, X; Jiang, H; Liu, L; Lu, Z; Meng, X; Song, X; Wang, J; Zheng, T	1
Buranrat, B; Kongpetch, S; Kukongviriyapan, U; Kukongviriyapan, V; Prawan, A	1
Eguchi, K; Hasegawa, S; Misuta, K; Mori, R; Murakami, T; Nakano, A; Sasaki, M; Tokuhisa, M	1
Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z	1
Akiyama, N; Ayata, S; Maruyama, Y; Tsukada, Y	1
Fujiwara, M; Inoue, K; Ito, N; Kubo, N; Maruyama, A; Nakayama, A; Ogiwara, H; Rokuhara, T; Shirozaki, T; Takasu, K; Takeuchi, N; Tsujimoto, K	1
Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sakabe, R; Sudo, T; Sueda, T; Uemura, K	1
Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R	1
Boadle, R; Hills, K; Mahajan, H; Nankivell, B; P'ng, CH; Yong, JL	1
Ishihara, T; Miyakawa, K; Sakai, Y; Sugiyama, H; Tomizawa, M; Tsuyuguchi, T; Yokosuka, O	1
Braconi, C; Huang, N; Kogure, T; Patel, T; Swenson, E	1
Mizuyama, Y; Nakagawa, H; Nishihara, T; Ono, Y; Shinto, O; Tamura, T	1
Hatano, E; Ikeda, K; Kamo, N; Mitsuyoshi, H; Mori, A; Nitta, T; Uemoto, S	1
Anazawa, T; Gotoh, M; Kenjo, A; Kimura, T; Saito, T; Sato, J; Sato, Y; Tsuchiya, T	1
Chang, Y; Littman, SJ; Mbeo, G	1
Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C	1
Ambrosino, G; Baiocchi, C; Costantin, G; Febbraro, A; Francescon, P; Guglielmi, R; Polistina, FA; Scalchi, P	1
Bechstein, WO; Gruber-Rouh, T; Naguib, NN; Nour-Eldin, NE; Trojan, J; Vogl, TJ; Zeuzem, S	1
Fukunaga, K; Hirata, Y; Iida, H; Kakuno, A; Morita, M; Murata, S; Nishigami, T; Tamura, M; Tani, S; Yamanaka, N	1
Borbath, I; Gigot, JF; Humblet, Y; Lai, R; Piessevaux, H; Sempoux, C; Verbrugghe, L	1
Doki, Y; Eguchi, H; Iwagami, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H	1
Akagi, K; Dono, K; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Miyake, M; Nagai, K; Shimano, T; Shimizu, J	1
Aoki, H; Arata, T; Fujiwara, Y; Kanazawa, T; Morihiro, T; Nakagawa, H; Ohara, T; Seita, M; Takehara, K; Takeuchi, H; Tanakaya, K	1
Blum, HE; Breidert, M; Euringer, W; Fischer, R; Harder, J; Kuhlmann, JB; Spangenberg, HC	1
Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K	1
Audrain, O; Boucher, E; Crouzet, L; Edeline, J; Le Du, F; Raoul, JL	1
Fukuoka, J; Hori, R; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Watanabe, T; Yoshioka, I	1
Audrain, O; Boucher, E; Boudjema, K; Le Roux, G; Manfredi, S; Mesbah, H; Pracht, M; Raoul, JL; Sulpice, L	1
Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Sudo, T; Sueda, T; Uemura, K	1
Anupindi, SA; Cantor, J; Lin, H; Matthews, RP; Rutstein, R	1
Abo, T; Isomoto, H; Nagayasu, T; Nanashima, A; Nonaka, T; Nonaka, Y; Uehara, M	1
Abe, T; Fujikawa, T; Kawashima, T; Maekawa, H; Shimoike, N; Shiraishi, K; Tada, S; Tanaka, A; Tanaka, H; Yoshimoto, Y	1
Alexandrescu, S; Becheanu, G; Buica, F; Croitoru, A; Diculescu, M; Dinu, I; Gheorghe, L; Gramaticu, I; Herlea, V; Hrehoret, D; Luca, I; Lupescu, I; Popescu, I; Simionov, I	1
Furukawa, K; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimizu, H; Takayashiki, T; Takeuchi, D; Yoshidome, H; Yoshitomi, H	1
Knox, JJ; Zhu, AX	1
Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H	1
Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Hayakumo, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Ohtsubo, I; Okazaki, T; Sawa, H; Shinozaki, K; Shinzeki, M; Shirakawa, S; Tanaka, M; Toyama, H; Ueno, K; Yoshida, Y	1
Hasuike, Y; Hirao, S; Iwagami, Y; Kira, T	1
Egawa, C; Hamanaka, M; Kanemura, T; Kato, T; Kawashima, H; Miki, H; Mukai, Y; Nakahira, S; Nakata, K; Okishiro, M; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H; Uchiyama, C	1
Aoyagi, H; Hasegawa, K; Iwata, N; Kaneko, J; Katsuta, E; Maejima, S; Takahata, T; Yoshida, T	1
Ajiki, T; Fukumoto, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Ohtsubo, I; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y	1
Chirita, D; Dumitrascu, T; Ionescu, M; Popescu, I	1
Alfieri, S; Cellini, N; Costamagna, G; Doglietto, GB; Luzi, S; Macchia, G; Morganti, AG; Smaniotto, D; Trodella, L; Valentini, V	1
Hedley, D; Knox, JJ; Moore, MJ; Oza, A; Pond, GR; Siu, LL	1
Hong, YS; Kang, JH; Lee, KS; Lee, MA; Woo, IS	1
Dai, L; Eng, C; Kindler, HL; Mani, S; Ramanathan, RK; Ramathan, RK; Remick, SC; Wade-Oliver, KT; Wong, MK	1
Brunner, TB; Meyer, T; Sauer, R; Schwab, D	1
Baus, S; Bleck, J; Chavan, A; Frericks, B; Galanski, M; Kirchhoff, T; Kubicka, S; Malek, N; Manns, MP; Merkesdal, S; Zender, L	1
Drebin, JA; Lin, LL; Linehan, DC; Myerson, R; Picus, J; Solis, J; Strasberg, SM; Tan, B; Thorstad, WL	1
Fuchs, M; Schepp, W	1
Jang, JS; Kang, JH; Kim, HG; Lee, GW; Lee, JS	1
Badalamenti, G; Cicero, G; Di Leo, R; Fulfaro, F; Gebbia, N; Gulotta, G; Russo, A; Santangelo, D; Tomasello, G; Valerio, MR; Verderame, F	1
Bajardi, E; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E	1
Adam, R; Bellin, MF; Bralet, MP; Guettier, C; Paule, B	1
Galle, PR; Kanzler, S; Moehler, M; Schadmand-Fischer, S; Schimanski, CC; Sprinzl, MF	1
Eichler, K; Hammerstingl, R; Heller, M; Hochmuth, K; Jacob, U; Scheller, A; Schwarz, W; Vogl, TJ; Zangos, S	1
Henson, R; Lang, M; Meng, F; Patel, T; Wehbe, H	1
Kondo, T; Matsuo, R; Moon, Y; Ohkohchi, N; Ohshiro, Y; Takeshima, T; Todoroki, T; Yamamoto, Y	1
Bleeker, G; Henson, R; Meng, F; Naus, PJ; Patel, T; Wehbe, H	1
Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y	1
Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H	1
Ajiki, T; Fujimori, T; Fujita, T; Hirata, K; Hori, H; Horiuchi, H; Kamigaki, T; Kuroda, Y; Mita, Y; Okazaki, T	1
Alberts, SR; Chari, ST; Gores, GJ; Kendrick, ML; Kim, GP; Martenson, JA; Roberts, LR; Rosen, CB	1
Kusano, F; Nagayama, K; Nitta, S; Sakai, Y; Tazawa, J	1
Charoentum, C; Chewaskulyong, B; Munprakan, S; Thongprasert, S	1
Bhargava, P; Blaszkowsky, L; Earle, CC; Fuchs, CS; Kulke, MH; Lehman, N; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX	1
Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA	1
Fakih, M; Gibbs, J; Iyer, RV; Javle, MM; Kepner, J; Kuvshinoff, B; Lawrence, D; Soehnlein, N	1
Balaa, FK; Carr, BI; Gamblin, TC; Geller, DA; Gusani, NJ; Marsh, JW; Steel, JL; Zajko, AB	1
Bauer, RW; Eichler, K; Selby, JB; Vogl, TJ; Zangos, S	1
Berster, J; Beuers, U; Böck, S; Graeb, C; Heinemann, V; Jacobs, T; Kolligs, FT; Schäfer, C; Schirra, J; Schönberg, SO; Thasler, W; Wilkowski, R; Zech, CJ	1
Baconnier, M; Bedenne, L; Boucher, E; Girault, C; Phelip, JM; Roblin, X	1
Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D	1
König, P; Kühr, T; Lhotta, K; Rumpelt, HJ; Thaler, J; Wöll, E	1
Daniele, B; De Vivo, R	1
Goulart, BH; Lynch, TJ; Martins, RG	1
Cabrera, E; Cortés, C; Gallardo, J; González, C; Rubio, B	1

Reviews

23 review(s) available for gemcitabine and Bile Duct Cancer

Article	Year
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. European journal of cancer (Oxford, England : 1990), 2022, Volume: 164 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic	2022
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review. Frontiers in immunology, 2022, Volume: 13 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged	2022
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial. Future oncology (London, England), 2023, Volume: 19, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Gemcitabine; Humans; Oxaliplatin	2023
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies. Frontiers in immunology, 2023, Volume: 14 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Gemcitabine; Humans; Immunosuppressive Agents; Tumor Microenvironment; United States	2023
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2023, Jun-08 Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing	2023
Case Report: Camrelizumab combined with gemcitabine and oxaliplatin in the treatment of advanced intrahepatic cholangiocarcinoma: a case report and literature review. Frontiers in immunology, 2023, Volume: 14 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Gemcitabine; Humans; Oxaliplatin	2023
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer. Future oncology (London, England), 2023, Volume: 19, Issue:34 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
Durvalumab: A Review in Advanced Biliary Tract Cancer. Targeted oncology, 2023, Volume: 18, Issue:6 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome	2023
Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review. Cancer treatment reviews, 2020, Volume: 91 Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Klatskin Tumor; Male; Middle Aged; Treatment Outcome	2020
[Cystic Duct Cancer with Postoperative Liver Metastasis That Achieved Complete Response after Gemcitabine Treatment - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholecystectomy; Cystic Duct; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Staging	2017
[Therapeutic advances in the management of biliary tract carcinoma]. Presse medicale (Paris, France : 1983), 2018, Volume: 47, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; France; Gemcitabine; Humans; Medical Oncology	2018
[A Distal Bile Duct Carcinoma Patient Who Underwent Surgical Resection for Liver Metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:3 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur	2018
Medical treatment for cholangiocarcinoma. Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39 Suppl 1 Topics: Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Hepatocyte Growth Factor; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-met; Randomized Controlled Trials as Topic; Receptors, Fibroblast Growth Factor	2019
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome	2014
HBV-associated intrahepatic cholangiocarcinoma with high serum alpha-fetoprotein: a case report with review of literature. BMC infectious diseases, 2016, 06-14, Volume: 16 Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; DNA, Viral; Gemcitabine; Guanine; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Liver; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Risk Factors; Tomography, X-Ray Computed	2016
A case of adenosquamous carcinoma of the lower bile duct diagnosed preoperatively via transpapillary biopsy. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2016, Volume: 113, Issue:8 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biopsy; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Gemcitabine; Humans; Male; Pancreaticoduodenectomy	2016
[A case of interstitial pneumonia induced by gemcitabine hydrochloride for unresectable bile duct cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:10 Topics: Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bilirubin; Deoxycytidine; Diuretics; Gemcitabine; Humans; Jaundice, Obstructive; Lung Diseases, Interstitial; Male; Pulse Therapy, Drug; Steroids; Tomography, X-Ray Computed	2009
[Chemotherapy in gallbladder carcinoma]. Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2010
[A case of intrahepatic cholangiocarcinoma with invasion to right adrenal gland]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Adrenal Glands; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Tomography, X-Ray Computed	2011
[Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Staging; Time Factors	2012
Treatment options for hepatobiliary and pancreatic cancer. Mayo Clinic proceedings, 2007, Volume: 82, Issue:5 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Ethanol; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis	2007
[Interdisciplinary diagnosis of and therapy for cholangiocarcinoma]. Zeitschrift fur Gastroenterologie, 2008, Volume: 46, Issue:1 Topics: Algorithms; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drainage; Endosonography; Gemcitabine; Hepatic Duct, Common; Humans; Klatskin Tumor; Liver Transplantation; Magnetic Resonance Imaging; Tomography, X-Ray Computed	2008
[Gemcitabine in the treatment of 4 patients with cholangiocarcinoma]. Revista medica de Chile, 2001, Volume: 129, Issue:8 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome	2001

Trials

69 trial(s) available for gemcitabine and Bile Duct Cancer

Article	Year
Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma. Annals of surgical oncology, 2022, Volume: 29, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor; Neoadjuvant Therapy; Pancreatic Neoplasms	2022
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 06-01, Volume: 28, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Ramucirumab; Vascular Endothelial Growth Factor Receptor-2	2022
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin. Annals of surgical oncology, 2022, Volume: 29, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Prospective Studies; Treatment Outcome	2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-03, Volume: 28, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chromatin Assembly and Disassembly; Deoxycytidine; Gemcitabine; Humans; Nivolumab	2022
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. British journal of cancer, 2022, Volume: 127, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mitogen-Activated Protein Kinase Kinases	2022
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01. Cancer, 2022, 10-01, Volume: 128, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ipilimumab; Male; Middle Aged; Nivolumab	2022
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology (Baltimore, Md.), 2023, 03-01, Volume: 77, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO). Oncology research and treatment, 2023, Volume: 46, Issue:3 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Treatment Outcome	2023
[GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience]. Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:2 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Neutropenia; Thrombocytopenia; Treatment Outcome	2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer, 2023, 05-15, Volume: 129, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans	2023
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nature communications, 2023, 03-11, Volume: 14, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology (Baltimore, Md.), 2023, 05-01, Volume: 77, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04). Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 07-05, Volume: 29, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neutropenia	2023
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). BMC cancer, 2023, May-22, Volume: 23, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine	2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. The Lancet. Oncology, 2023, Volume: 24, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged	2023
Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2023, Jun-08 Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing	2023
Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial. Hepatology (Baltimore, Md.), 2023, 10-01, Volume: 78, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study. Anticancer research, 2023, Volume: 43, Issue:9 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma in Situ; Cholangiocarcinoma; Erlotinib Hydrochloride; Gallbladder Neoplasms; Gemcitabine; Humans; Pemetrexed; Prospective Studies; Salvage Therapy	2023
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA oncology, 2020, Jan-01, Volume: 6, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Treatment Outcome	2020
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. Anticancer research, 2020, Volume: 40, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome	2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of hepatology, 2020, Volume: 73, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Global Health; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Analysis	2020
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines; Treatment Outcome	2020
Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). The oncologist, 2021, Volume: 26, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bile Duct Neoplasms; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Treatment Outcome; Vascular Endothelial Growth Factor A	2021
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study. Oncology, 2021, Volume: 99, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Prognosis; Prospective Studies; Survival Rate	2021
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer medicine, 2017, Volume: 6, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Treatment Outcome	2017
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PloS one, 2018, Volume: 13, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gallbladder Neoplasms; Gemcitabine; Gene Amplification; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis	2018
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecologic oncology, 2018, Volume: 148, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome	2018
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. The British journal of surgery, 2018, Volume: 105, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Survival Analysis; Treatment Outcome	2018
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Anticancer research, 2018, Volume: 38, Issue:4 Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur	2018
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA oncology, 2018, 12-01, Volume: 4, Issue:12 Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Treatment Outcome	2018
Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. BMJ open, 2018, 10-15, Volume: 8, Issue:10 Topics: Bile Duct Neoplasms; Cisplatin; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Klatskin Tumor; Netherlands; Quality of Life; Radiosurgery; Treatment Outcome	2018
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2019, Volume: 51, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin	2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA oncology, 2019, Jun-01, Volume: 5, Issue:6 Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome	2019
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome	2013
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins	2013
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome	2013
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:8 Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma; Cetuximab; Cholangiocarcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins	2014
Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-15, Volume: 20, Issue:16 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Epitopes; Female; Follow-Up Studies; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Survival Rate; T-Lymphocytes, Cytotoxic; Vaccination; WT1 Proteins	2014
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors	2014
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-20, Volume: 33, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate	2015
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial BMC cancer, 2015, Jul-31, Volume: 15 Topics: Australia; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Denmark; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Germany; Humans; Netherlands; Prognosis; Treatment Outcome; United Kingdom	2015
Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. Journal of hepato-biliary-pancreatic sciences, 2015, Volume: 22, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome	2015
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). Cancer, 2016, Feb-15, Volume: 122, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Treatment Outcome	2016
Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study. Anticancer research, 2016, Volume: 36, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Treatment Outcome	2016
Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. Oncotarget, 2016, May-03, Volume: 7, Issue:18 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Klatskin Tumor; Male; Middle Aged; Oxonic Acid; Tegafur	2016
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. American journal of clinical oncology, 2018, Volume: 41, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quality of Life; Survival Rate	2018
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate	2008
[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer]. Przeglad lekarski, 2008, Volume: 65, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate	2008
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. Japanese journal of clinical oncology, 2010, Volume: 40, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome	2010
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. British journal of cancer, 2009, Dec-01, Volume: 101, Issue:11 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult	2009
Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). American journal of clinical oncology, 2011, Volume: 34, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome	2011
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome	2011
Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Annals of surgical oncology, 2011, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome	2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Thymidylate Synthase	2011
Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. European journal of gastroenterology & hepatology, 2012, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Deoxycytidine; Epidemiologic Methods; Female; Gelatin Sponge, Absorbable; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome	2012
Concomitant gemcitabine (Gemzar) and extended nodes irradiation in the treatment of pancreatic and biliary carcinoma: a phase I study. Onkologie, 2003, Volume: 26, Issue:4 Topics: Aged; Bile Duct Neoplasms; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hepatic Duct, Common; Humans; Infusions, Intravenous; Klatskin Tumor; Lymphatic Irradiation; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant	2003
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome	2004
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. American journal of clinical oncology, 2004, Volume: 27, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis	2004
Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World journal of gastroenterology, 2005, Feb-28, Volume: 11, Issue:8 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Embolization, Therapeutic; Female; Gemcitabine; Humans; Male; Middle Aged; Quality of Life; Treatment Outcome	2005
A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. American journal of clinical oncology, 2005, Volume: 28, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intestine, Small; Life Tables; Lymphatic Irradiation; Male; Middle Aged; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome	2005
Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. American journal of clinical oncology, 2006, Volume: 29, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Middle Aged; Survival Analysis	2006
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate	2006
Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged	2006
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. American journal of clinical oncology, 2006, Volume: 29, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome	2006
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Digestive diseases and sciences, 2008, Volume: 53, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis	2008
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer, 2007, Sep-15, Volume: 110, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome	2007
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Annals of surgical oncology, 2007, Volume: 14, Issue:11 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome	2007
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. American journal of clinical oncology, 2008, Volume: 31, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis	2008
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Remission Induction	2001

Other Studies

236 other study(ies) available for gemcitabine and Bile Duct Cancer

Article	Year
Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study. American journal of clinical oncology, 2021, 10-01, Volume: 44, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Preoperative Period; Retrospective Studies; Treatment Outcome	2021
Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma". Journal of hepato-biliary-pancreatic sciences, 2022, Volume: 29, Issue:4 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor	2022
Comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma". Journal of hepato-biliary-pancreatic sciences, 2022, Volume: 29, Issue:4 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor	2022
Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial. Biomolecules, 2021, 11-03, Volume: 11, Issue:11 Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Middle Aged	2021
MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. International journal of biological sciences, 2022, Volume: 18, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Down-Regulation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; MicroRNAs; Xenograft Model Antitumor Assays	2022
Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surgical oncology, 2022, Volume: 40 Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed	2022
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis. Gut and liver, 2022, 09-15, Volume: 16, Issue:5 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Propensity Score	2022
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Scientific reports, 2022, 01-19, Volume: 12, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cholangitis; Cholestasis; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Treatment Outcome	2022
Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Life sciences, 2022, May-01, Volume: 296 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; TOR Serine-Threonine Kinases	2022
Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma. Frontiers in public health, 2022, Volume: 10 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Glucose; Humans	2022
Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin. Clinics and research in hepatology and gastroenterology, 2022, Volume: 46, Issue:8 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Oxaliplatin	2022
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells. Scientific reports, 2022, 04-13, Volume: 12, Issue:1 Topics: B7-H1 Antigen; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; CD3 Complex; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; T-Lymphocytes, Cytotoxic	2022
[Successful R0 Resection of Hilar Cholangiocarcinoma Invading the Inferior Vena Cava through Left Trisegmentectomy with Combined Resection of the Portal Vein and Inferior Vena Cava after Gemcitabine/Cisplatin Combination Chemotherapy-A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:4 Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Portal Vein; Vena Cava, Inferior	2022
Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma. Current oncology (Toronto, Ont.), 2022, 03-23, Volume: 29, Issue:4 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholestasis; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Radiofrequency Ablation; Retrospective Studies; Treatment Outcome	2022
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma. PloS one, 2022, Volume: 17, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome	2022
Lactic acidosis promotes aggressive features of cholangiocarcinoma cells via upregulating ALDH1A3 expression through EGFR axis. Life sciences, 2022, Aug-01, Volume: 302 Topics: Acidosis, Lactic; Aldehydes; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; ErbB Receptors; Gemcitabine; Humans; Tumor Microenvironment	2022
Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series. Current oncology (Toronto, Ont.), 2022, 05-17, Volume: 29, Issue:5 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Transplantation; Male; Neoadjuvant Therapy	2022
Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma. The oncologist, 2022, 06-08, Volume: 27, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Photochemotherapy	2022
Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China. Frontiers in immunology, 2022, Volume: 13 Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Quinolines; Retrospective Studies	2022
Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles. PeerJ, 2022, Volume: 10 Topics: Acetylcholine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Metabolome; RNA, Ribosomal, 16S	2022
A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy. Clinical journal of gastroenterology, 2022, Volume: 15, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Gemcitabine; Humans	2022
Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery. Clinical journal of gastroenterology, 2023, Volume: 16, Issue:1 Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male	2023
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery, 2023, Volume: 173, Issue:2 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies	2023
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. Journal of vascular and interventional radiology : JVIR, 2023, Volume: 34, Issue:4 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Cisplatin; Gemcitabine; Humans; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2023
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma. British journal of cancer, 2023, Volume: 128, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Thrombospondins	2023
Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. Frontiers in immunology, 2022, Volume: 13 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans	2022
Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study. Oncology reports, 2023, Volume: 49, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Retrospective Studies; Treatment Outcome	2023
Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line, ICC-X3. Human cell, 2023, Volume: 36, Issue:2 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line; Cell Line, Tumor; Cholangiocarcinoma; Gemcitabine; Humans	2023
[A Case of an Advanced Intrahepatic Cholangiocarcinoma Effectively Treated by Conversion Surgery after Neoadjuvant Chemotherapy of Gemcitabine, Cisplatin and S-1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography	2022
Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity. Cells, 2023, 02-22, Volume: 12, Issue:5 Topics: Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mice	2023
Response to letter to the editor: Use, response and outcomes of second line chemotherapy in patients with advanced biliary tract cancers. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:4 Topics: Bile Duct Neoplasms; Biliary Tract Neoplasms; Gemcitabine; Humans	2023
Futibatinib (Lytgobi) for cholangiocarcinoma. The Medical letter on drugs and therapeutics, 2023, 04-17, Volume: 65, Issue:1674 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Gemcitabine; Humans	2023
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer. Cancer research and treatment, 2023, Volume: 55, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Mutation; Prospective Studies; Transcription Factors	2023
Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation. International journal of biological sciences, 2023, Volume: 19, Issue:9 Topics: Afatinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Mucin-4; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt	2023
PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK. Science translational medicine, 2023, 07-12, Volume: 15, Issue:704 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Gemcitabine; Humans; Nucleosides; Phosphorylation; PTEN Phosphohydrolase	2023
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver international : official journal of the International Association for the Study of the Liver, 2023, Volume: 43, Issue:8 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Gemcitabine; Humans	2023
Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial. Hepatology (Baltimore, Md.), 2023, 10-01, Volume: 78, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans	2023
Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2/glycolysis signaling. Acta biochimica et biophysica Sinica, 2023, Jul-25, Volume: 55, Issue:9 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Epinephrine; Gemcitabine; Glycolysis; Humans; Norepinephrine; Receptors, Adrenergic, beta-2	2023
An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study. BMC gastroenterology, 2023, Aug-01, Volume: 23, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Cohort Studies; Deoxycytidine; East Asian People; Gemcitabine; Humans	2023
Induction of apoptotic cell death of cholangiocarcinoma cells by tiliacorinine from Tiliacora triandra: A mechanistic insight. Biochimica et biophysica acta. General subjects, 2023, Volume: 1867, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Gemcitabine; Humans; Mice; Molecular Docking Simulation; Proto-Oncogene Proteins c-akt	2023
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma. Annals of surgical oncology, 2024, Volume: 31, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Infusion Pumps; Liver; Male; Retrospective Studies; Treatment Outcome	2024
The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines. Asian Pacific journal of cancer prevention : APJCP, 2019, 09-01, Volume: 20, Issue:9 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Octamer Transcription Factor-3; Tumor Cells, Cultured; Tumor Microenvironment	2019
Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells. International immunopharmacology, 2020, Volume: 78 Topics: Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Dendritic Cells; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; T-Lymphocytes, Cytotoxic	2020
Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study. Hepatobiliary & pancreatic diseases international : HBPD INT, 2020, Volume: 19, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Prognosis; Retrospective Studies; Risk Factors; Survival Rate	2020
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell death and differentiation, 2020, Volume: 27, Issue:8 Topics: Adaptor Proteins, Signal Transducing; Amyloid Precursor Protein Secretases; Animals; Benzazepines; Bile Duct Neoplasms; Calcium-Binding Proteins; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 13; Mice, Nude; Microvessels; Neovascularization, Pathologic; Receptor, Notch1; Reproducibility of Results; RNA, Messenger; Signal Transduction; Transcriptome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2020
Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study. American journal of clinical oncology, 2020, Volume: 43, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Drainage; Female; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Time Factors	2020
[A Case of Liver Metastases of Ampullary Carcinoma with Clinical Complete Response Treated with Gemcitabine plus Cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13 Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Treatment Outcome	2019
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma. JAMA oncology, 2020, 06-01, Volume: 6, Issue:6 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Oxaliplatin	2020
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply. JAMA oncology, 2020, 06-01, Volume: 6, Issue:6 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Oxaliplatin	2020
De novo perihilar cholangiocarcinoma arising in the allograft liver 15 years post-transplantation for biliary atresia. Pathology international, 2020, Volume: 70, Issue:8 Topics: Adenocarcinoma; Allografts; Bile Duct Neoplasms; Biliary Atresia; Child; Cholangiocarcinoma; Cisplatin; Constriction, Pathologic; Deoxycytidine; Female; Gemcitabine; Humans; Immunosuppressive Agents; Liver; Liver Transplantation; Neoplasm Recurrence, Local; Postoperative Complications; Young Adult	2020
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel. Current oncology (Toronto, Ont.), 2020, Volume: 27, Issue:2 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms	2020
Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma. Scientific reports, 2020, 07-02, Volume: 10, Issue:1 Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts; Chemotherapy, Adjuvant; Combined Modality Therapy; Constriction, Pathologic; Deoxycytidine; Electroporation; Female; Follow-Up Studies; Gemcitabine; Humans; Klatskin Tumor; Laparotomy; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Treatment Outcome	2020
Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: a case report. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:12 Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Electrochemotherapy; Gemcitabine; Humans; Male; Tomography, X-Ray Computed	2020
Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma. World journal of gastroenterology, 2020, Aug-21, Volume: 26, Issue:31 Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug-Eluting Stents; Feasibility Studies; Gemcitabine; Humans; Mice; Mice, Nude; Stents; Swine	2020
Thyroid Follicle-Like Cholangiocarcinoma in Liver: a Novel Variant and What We Know So Far? Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Immunohistochemistry; India	2021
High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin. BMC cancer, 2020, Sep-23, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Blood Platelets; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphocytes; Male; Middle Aged; Prognosis; Retrospective Studies	2020
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. International journal of molecular sciences, 2020, Oct-14, Volume: 21, Issue:20 Topics: Animals; Anticholesteremic Agents; Antimetabolites, Antineoplastic; Apoptosis; Atorvastatin; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Connective Tissue Growth Factor; Contractile Proteins; Cysteine-Rich Protein 61; Deoxycytidine; Drug Combinations; Drug Interactions; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Muscle Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-yes; Repressor Proteins	2020
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Scientific reports, 2020, 10-28, Volume: 10, Issue:1 Topics: Animals; Apoptosis; bcl-X Protein; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Cyclic N-Oxides; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase 9; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Histones; Humans; Indolizines; Inhibitory Concentration 50; Ki-67 Antigen; Male; Mice; Mice, Inbred NOD; Proto-Oncogene Proteins c-bcl-2; Pyridinium Compounds; Xenograft Model Antitumor Assays	2020
Perihilar clear cell cholangiocarcinoma: an often-diagnostic challenge. BMJ case reports, 2020, Dec-22, Volume: 13, Issue:12 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biopsy; Cholangiography; Cholangiopancreatography, Magnetic Resonance; Cisplatin; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Fatal Outcome; Gemcitabine; Hepatic Duct, Common; Humans; Klatskin Tumor; Male; Palliative Care; Positron Emission Tomography Computed Tomography	2020
Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis. Cell death & disease, 2021, 01-12, Volume: 12, Issue:1 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Middle Aged; Neoplastic Stem Cells; RNA, Long Noncoding; Transcription Factors	2021
Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. American journal of surgery, 2021, Volume: 221, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Graft Survival; Hepatectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies	2021
The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma. Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:3 Topics: Adenosylhomocysteinase; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Proliferation; Cell Transformation, Neoplastic; Cholangiocarcinoma; Co-Repressor Proteins; Cyclic AMP Response Element-Binding Protein A; Deoxycytidine; Fetal Proteins; Gemcitabine; Gene Fusion; Liver Neoplasms, Experimental; Mice; Microtubule-Associated Proteins; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Vesicular Transport Proteins	2021
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. Oncology, 2021, Volume: 99, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Palliative Care; Platinum; Prognosis; Survival Analysis; Treatment Outcome	2021
Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway. Oncogene, 2021, Volume: 40, Issue:25 Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Cytoskeleton; Deoxycytidine; Endothelial Cells; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction	2021
Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis. Journal of hepato-biliary-pancreatic sciences, 2021, Volume: 28, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor; Propensity Score; Retrospective Studies	2021
The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis. Scandinavian journal of gastroenterology, 2021, Volume: 56, Issue:8 Topics: Benzylamines; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Cholangiocarcinoma; Cyclams; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Receptors, CXCR4	2021
Chemotherapy with gemcitabine for unresectable intrahepatic cholangiocarcinoma in a patient undergoing maintenance hemodialysis. Clinical journal of gastroenterology, 2021, Volume: 14, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Renal Dialysis	2021
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells. International journal of molecular sciences, 2021, Jul-30, Volume: 22, Issue:15 Topics: Antineoplastic Agents; Autophagy; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Glycine; Humans; Radiation-Sensitizing Agents; Sulfones	2021
The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Male; Matched-Pair Analysis; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome	2017
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Molecular carcinogenesis, 2017, Volume: 56, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Carcinogenesis; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGA Proteins; Humans; Male; Mice; Middle Aged; Oligonucleotide Array Sequence Analysis; RNA, Messenger; Time Factors	2017
Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma. Annals of surgical oncology, 2017, Volume: 24, Issue:8 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Expression Profiling; Humans; Male; MicroRNAs; Middle Aged; PPAR gamma; Prognosis; Survival Rate; Tumor Cells, Cultured; Up-Regulation	2017
Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017, Volume: 19, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cholangiocarcinoma; Databases, Factual; Deoxycytidine; Europe; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Staging; North America; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2017
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report. Journal of medical case reports, 2017, Sep-26, Volume: 11, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Maintenance Chemotherapy; Neoplasm Metastasis; Peritoneal Neoplasms; Splenic Neoplasms; Time Factors; Treatment Outcome	2017
Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment. Oncology, 2018, Volume: 94, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; C-Reactive Protein; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies	2018
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma. Anticancer research, 2017, Volume: 37, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
Prognostic Factors and Patterns of Locoregional Failure After Surgical Resection in Patients With Cholangiocarcinoma Without Adjuvant Radiation Therapy: Optimal Field Design for Adjuvant Radiation Therapy. International journal of radiation oncology, biology, physics, 2017, 11-15, Volume: 99, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Confidence Intervals; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors	2017
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer. Anticancer research, 2018, Volume: 38, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids	2018
When Lightning Strikes Twice. Digestive diseases and sciences, 2018, Volume: 63, Issue:10 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Second Primary; Pancreaticoduodenectomy; Reoperation; Tomography, X-Ray Computed; Treatment Outcome	2018
Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada. Journal of surgical oncology, 2018, Volume: 117, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Klatskin Tumor; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate	2018
Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy. Annals of surgical oncology, 2018, Volume: 25, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cytoplasm; Deoxycytidine; Disease-Free Survival; Drug Combinations; ELAV-Like Protein 1; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur	2018
[A Case of Locally Advanced Intrahepatic Cholangiocarcinoma Successfully Treated by Conversion Surgery after Hepatic Arterial Infusion Chemotherapy and Radiation Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:4 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged	2018
Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma. Anticancer research, 2018, Volume: 38, Issue:5 Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Transdifferentiation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Metronidazole; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Spheroids, Cellular	2018
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. The International journal of biological markers, 2018, Volume: 33, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bilirubin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hepatitis B; Humans; Male; Middle Aged; Prognosis; Retrospective Studies	2018
The Strategy of Treatment for Mid to Distal Cholangiocarcinoma after Surgical Resection. The American surgeon, 2018, Jun-01, Volume: 84, Issue:6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome	2018
Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. Biomaterials, 2018, Volume: 183 Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Chlorophyll; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Heterografts; Humans; Immunomodulation; Lasers; Liposomes; Mice, Inbred BALB C; Mice, Nude; Phosphatidylethanolamines; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols	2018
Synchronous Adeno-squamous Carcinoma of Gallbladder and Adenocarcinoma of Common Bile Duct: Twin Trouble. Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Cisplatin; Common Bile Duct; Deoxycytidine; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreaticojejunostomy; Treatment Outcome; Ultrasonography	2019
SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance. British journal of cancer, 2018, Volume: 119, Issue:11 Topics: Antineoplastic Agents; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Proliferation; Cholangiocarcinoma; Chronic Disease; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Diseases; SOX9 Transcription Factor; Survival Analysis; Treatment Outcome	2018
Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Photochemotherapy; Retrospective Studies; Treatment Outcome	2019
[A Case of Long-Term Survival of a Patient with Cholangiocarcinoma and Liver Metastatic Recurrence Who Responded to Gemcitabine plus Cisplatin Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Recurrence, Local	2018
Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression. Cancer medicine, 2019, Volume: 8, Issue:3 Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mixed Function Oxygenases; Proto-Oncogene Proteins; Treatment Outcome; Xenograft Model Antitumor Assays	2019
[Successful R0 Resection of Hilar Cholangiocarcinoma by Extrahepatic Bile Duct Resection Due to Accompanying Liver Dysfunction after Neoadjuvant Gemcitabine/Cisplatin/S-1 Combination Chemotherapy-A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Klatskin Tumor; Male; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography	2019
[A Case of Liver Metastasis of Intrahepatic Cholangiocarcinoma That Achieved Clinical Complete Response after Gemcitabine and Cisplatin Combination Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local	2019
A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin. Clinical journal of gastroenterology, 2019, Volume: 12, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Pancreaticoduodenectomy; Positron-Emission Tomography; Tomography, X-Ray Computed	2019
The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma. Anticancer research, 2019, Volume: 39, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Plastic Surgery Procedures; Pyridines; Recurrence; Tegafur	2019
Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location. Scandinavian journal of gastroenterology, 2019, Volume: 54, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Palliative Care; Prognosis; Republic of Korea; Retrospective Studies	2019
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. Anticancer research, 2019, Volume: 39, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Risk Factors; Time Factors	2019
Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach. Hepatology international, 2019, Volume: 13, Issue:4 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Genes, Neoplasm; Humans; Male; Middle Aged; Mutation; Prognosis; Republic of Korea; Retrospective Studies; RNA, Neoplasm; United States; Up-Regulation	2019
[A case of inoperable advanced bile duct cancer treated effectively with combined chemotherapy of gemcitabine and S-1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur	2013
Curative resection of hilar cholangiocarcinoma in a 25-year-old woman: report of a case. Surgery today, 2014, Volume: 44, Issue:7 Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Hepatectomy; Humans; Lymphatic Metastasis; Mutation; Neoplasm Staging; Pancreatic Ducts; Portal Vein; Treatment Outcome; Tumor Suppressor Protein p53	2014
Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Gemcitabine; Hepatectomy; Mice; Mice, Inbred Strains; Mice, Knockout; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras); Risk Factors; Survival Rate; Tumor Suppressor Protein p53	2013
Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor. Pathology international, 2013, Volume: 63, Issue:4 Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Failure; Middle Aged	2013
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies	2013
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Peripheral Nerves; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome	2013
Adjuvant chemotherapy in resectable cholangiocarcinoma patients. Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome	2013
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prognosis; Retrospective Studies; Survival Rate	2013
miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PloS one, 2013, Volume: 8, Issue:10 Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3; Caspase 7; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Transcriptome	2013
Adjuvant surgery for advanced extrahepatic cholangiocarcinoma. World journal of gastroenterology, 2013, Oct-28, Volume: 19, Issue:40 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lymph Node Excision; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreaticoduodenectomy; Tomography, X-Ray Computed; Treatment Outcome	2013
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Oncology reports, 2014, Volume: 31, Issue:2 Topics: Adenosine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Polycomb Repressive Complex 2; RNA Interference; RNA, Small Interfering	2014
[A surgical case of peritoneal dissemination metastasis of bile duct carcinoma after pancreaticoduodenectomy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreaticoduodenectomy; Peritoneal Neoplasms; Recurrence	2013
Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents. Journal of experimental & clinical cancer research : CR, 2014, Jan-24, Volume: 33 Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; NAD(P)H Dehydrogenase (Quinone); RNA, Small Interfering; Tumor Suppressor Protein p53	2014
Science to practice: Can we turn the undesired heating effects of MR imaging into effective cancer therapies? Radiology, 2014, Volume: 270, Issue:2 Topics: Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging	2014
Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study. Radiology, 2014, Volume: 270, Issue:2 Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Chromatography, High Pressure Liquid; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Mice; Radio Waves; Swine	2014
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater. International journal of oncology, 2014, Volume: 44, Issue:4 Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Glycogen; Glypicans; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured	2014
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Axitinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Imidazoles; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience. Chemotherapy, 2013, Volume: 59, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome	2013
Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma. Gut and liver, 2014, Volume: 8, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Photochemotherapy; Treatment Outcome	2014
Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine. Oncology reports, 2014, Volume: 32, Issue:2 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans	2014
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Severity of Illness Index	2014
Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. British journal of cancer, 2014, Sep-23, Volume: 111, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cross-Sectional Studies; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins	2014
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC gastroenterology, 2014, Aug-13, Volume: 14 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome	2014
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. Anticancer research, 2014, Volume: 34, Issue:11 Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Gemcitabine; HLA-DR Antigens; Humans; Immunotherapy; Interferon-gamma; Lymphatic Metastasis; Middle Aged; Mucin-1; Peritoneal Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; WT1 Proteins	2014
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization. Transplantation proceedings, 2014, Volume: 46, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Calcineurin Inhibitors; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Incidental Findings; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prognosis; Sirolimus; Survival Analysis; Treatment Outcome	2014
Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series. Medicine, 2014, Volume: 93, Issue:28 Topics: Adult; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Therapy, Combination; Fatal Outcome; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Thymidine Phosphorylase; Tomography, X-Ray Computed	2014
[Concurrent chemoradiotherapy for locally advanced unresectable extrahepatic cholangiocarcinoma: a report of 19 cases]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2014, Volume: 43, Issue:6 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Survival Rate	2014
Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. Naunyn-Schmiedeberg's archives of pharmacology, 2015, Volume: 388, Issue:6 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Glutamate-Cysteine Ligase; Glutathione S-Transferase pi; Heme Oxygenase-1; Humans; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; RNA, Messenger; RNA, Small Interfering	2015
[A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness	2014
[A long term survival case of hilar cholangiocarcinoma with multiple metastases treated with chemotherapy and operation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Catheter Ablation; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Oxonic Acid; Tegafur	2014
[Long-term survivor of unresectable bile duct cancer complicated with sclerosing cholangitis treated with chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans	2014
[A case of curatively resected advanced intrahepatic cholangiocellular carcinoma through effective response to neoadjuvant chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Surgical Procedures; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Hepatectomy; Humans; Male; Neoadjuvant Therapy	2014
[A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Lymph Node Excision; Oxonic Acid; Peritoneal Neoplasms; Tegafur	2014
Severe ischemic colitis after treatment of bile-duct cancer using gemcitabine and cisplatin. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:4 Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cisplatin; Colitis, Ischemic; Deoxycytidine; Gemcitabine; Humans; Male	2015
Locally Advanced Intrahepatic Cholangiocarcinoma: Complete Pathologic Response to Neoadjuvant Chemotherapy Followed by Left Hepatic Trisectionectomy and Caudate Lobectomy. Digestive diseases and sciences, 2015, Volume: 60, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biopsy; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Hepatectomy; Humans; Male; Neoadjuvant Therapy; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2015
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. International journal of oncology, 2015, Volume: 47, Issue:1 Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Paclitaxel	2015
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. BMC cancer, 2015, May-22, Volume: 15 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2015
Consensus conference on hilar cholangiocarcinoma. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2015, Volume: 17, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biopsy; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Deoxycytidine; Embolization, Therapeutic; Gemcitabine; Humans; Klatskin Tumor; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Staging; Portal Vein; Tomography, Spiral Computed; Treatment Outcome	2015
Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Survival Rate	2016
Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. International journal of oncology, 2015, Volume: 47, Issue:4 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Transcriptome	2015
Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukemia Inhibitory Factor; Leukemia Inhibitory Factor Receptor alpha Subunit; Microscopy, Fluorescence; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction	2015
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PloS one, 2015, Volume: 10, Issue:11 Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Mucins; Neoplasm Transplantation; Phthalazines; Pyridines	2015
[A Long-Term Survival Case of Unresectable Hilar Bile Duct Cancer Treated with Gemcitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:11 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Time Factors; Treatment Outcome	2015
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer, 2016, Mar-01, Volume: 122, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate	2016
[Long Term Survival in a Case of Hilar Cholangiocarcinoma Treated with Chemotherapy and Surgery]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12 Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Male; Oxonic Acid; Pancreatectomy; Tegafur; Time Factors; Treatment Outcome	2015
[A Patient with Three-Year Relapse-Free Survival after Surgical Resection for Lung and Liver Metastases of Cholangiocarcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Recurrence; Tegafur	2015
Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma. Gut and liver, 2016, May-23, Volume: 10, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Randomized Controlled Trials as Topic; Stents; Treatment Outcome	2016
Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells. Oncology reports, 2016, Volume: 35, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Shape; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Peptides, Cyclic	2016
Classification of Gemcitabine resistant Cholangiocarcinoma cell lines using synchrotron FTIR microspectroscopy. Journal of biophotonics, 2017, Volume: 10, Issue:3 Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Microscopy; Neoplasm Transplantation; Phenotype; Sensitivity and Specificity; Spectroscopy, Fourier Transform Infrared; Synchrotrons	2017
[Klatskin tumor - a case report]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2016, Volume: 40, Issue:236 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Remission Induction; Stents	2016
Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. The oncologist, 2016, Volume: 21, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged	2016
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo. Anti-cancer drugs, 2016, Volume: 27, Issue:7 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays	2016
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study. Digestion, 2016, Volume: 93, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Male; Middle Aged; Palliative Care; Retrospective Studies; Treatment Outcome	2016
Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation. Journal of hepato-biliary-pancreatic sciences, 2016, Volume: 23, Issue:7 Topics: Anoikis; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Phosphorylation; Reference Values; Signal Transduction; STAT3 Transcription Factor; Tyrphostins	2016
Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surgery today, 2017, Volume: 47, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome	2017
Primary Poorly Differentiated Squamous Cell Carcinoma of the Extrahepatic Bile Duct. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local	2016
[Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Oxonic Acid; Tegafur; Treatment Outcome	2016
Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma. Jornal brasileiro de nefrologia, 2016, Volume: 38, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans	2016
Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo. Oncology reports, 2016, Volume: 36, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Male; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays	2016
hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. The oncologist, 2016, Volume: 21, Issue:12 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome	2016
A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:4 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreaticoduodenectomy; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed	2017
BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma. Molecular cancer, 2017, 01-25, Volume: 16, Issue:1 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mutation; RNA, Long Noncoding; Tumor Suppressor Proteins; Ubiquitin Thiolesterase	2017
[Antitumor Effects of a Combined Treatment with Bortezomib and Gemcitabine in Bile Duct Cancer Cell Lines]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bortezomib; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; NF-kappa B; Signal Transduction	2016
[Surgical Resection after Gemcitabine plus Cisplatin Chemotherapy for Intrahepatic Cholangiocarcinoma with Multiple Lymph Node Metastases - Report of a Case]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Hepatectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy	2016
[A Case of Peritoneal Dissemination of Hilar Cholangiocarcinoma Presenting with Hematuria Six Years after Radical Surgery]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Hematuria; Humans; Klatskin Tumor; Male; Peritoneal Neoplasms; Time Factors	2016
[A Case of Lymph Node Metastasis of Intrahepatic Bile Duct Cancer Successfully Treated Using Multidisciplinary Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Recurrence; Tegafur; Treatment Outcome	2016
Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma. PloS one, 2017, Volume: 12, Issue:2 Topics: Animals; Antibodies, Monoclonal; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Molecular Targeted Therapy; Neural Cell Adhesion Molecule L1; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays	2017
Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins. Oncotarget, 2017, Jun-27, Volume: 8, Issue:26 Topics: Aged; alpha Karyopherins; Antineoplastic Agents; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Transport; RNA Interference; Tumor Burden	2017
Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy. Medical science monitor : international medical journal of experimental and clinical research, 2017, Feb-13, Volume: 23 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Cisplatin; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Starch	2017
Cholangiocellular Carcinoma. Digestion, 2017, Volume: 95, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Incidence; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Palliative Care; Precision Medicine; Survival Rate	2017
[Chemotherapy with gemcitabine after non-curative resection of bile duct cancer--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7 Topics: Aged; Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Tomography, X-Ray Computed	2008
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncology reports, 2008, Volume: 20, Issue:2 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins	2008
The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncology reports, 2008, Volume: 20, Issue:4 Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cholangiocarcinoma; Deoxycytidine; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Liver Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases	2008
CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma. Journal of gastrointestinal cancer, 2007, Volume: 38, Issue:2-4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; CA-19-9 Antigen; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome	2007
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:5 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Camellia sinensis; Catechin; Cell Line, Tumor; Cholangiocarcinoma; Cytochromes c; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitomycin; Plant Extracts	2009
Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Hepatectomy; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Care; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2009
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovascular and interventional radiology, 2009, Volume: 32, Issue:6 Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoembolization, Therapeutic; Cholangiocarcinoma; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome	2009
Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma. World journal of gastroenterology, 2009, Sep-28, Volume: 15, Issue:36 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Radiography	2009
[A case of unresectable hilar bile duct cancer responding to chemo-radiotherapy by gemcitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:10 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Duodenal Neoplasms; Fatal Outcome; Female; Gemcitabine; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Radiography	2009
A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy. World journal of gastroenterology, 2009, Nov-07, Volume: 15, Issue:41 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Drug Therapy; Female; Gemcitabine; Humans; Oxonic Acid; Tegafur; Treatment Outcome	2009
[Two cases of inoperable advanced bileduct cancer treated effectively with a gemcitabine/cisplatin combination]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoembryonic Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Stents	2009
[The possibility of local control of cancer by neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy	2009
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma. Zeitschrift fur Gastroenterologie, 2010, Volume: 48, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cholestasis, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Duodenoscopy; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Hematoporphyrins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Photochemotherapy; Photosensitizing Agents; Stents; Treatment Outcome	2010
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer science, 2010, Volume: 101, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, SCID; Microtubule-Associated Proteins; Neoplasm Proteins; Specific Pathogen-Free Organisms	2010
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie, 2010, Volume: 33, Issue:1-2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate	2010
Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis. Cancer letters, 2010, Oct-01, Volume: 296, Issue:1 Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cisplatin; Deoxycytidine; DNA Repair; DNA Replication; Fibroblasts; Foreskin; Gemcitabine; Gene Knockdown Techniques; Gene Silencing; Humans; In Situ Nick-End Labeling; Male; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection	2010
Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2010, Volume: 31, Issue:4 Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Imidazoles; Immunoprecipitation; Mutation; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2010
Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World journal of gastroenterology, 2010, May-21, Volume: 16, Issue:19 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Dicumarol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Glutathione; Humans; Membrane Potential, Mitochondrial; NAD(P)H Dehydrogenase (Quinone); NF-kappa B; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Tumor Suppressor Protein p53	2010
[A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for bile duct cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:5 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Methylprednisolone; Tomography, X-Ray Computed	2010
[Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed	2010
[An effective case of gemcitabine therapy with post-operative peritoneal recurrence of intrahepatic cholangiocarcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:8 Topics: Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver; Male; Middle Aged; Peritoneal Neoplasms; Recurrence; Remission Induction; Tomography, X-Ray Computed	2010
Myelinoid bodies in a patient with membranoproliferative glomerulonephritis. Pathology, 2010, Volume: 42, Issue:7 Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Inclusion Bodies; Kidney Glomerulus; Male; Microscopy, Electron, Transmission; Middle Aged	2010
[Case of intrahepatic cholangiocarcinoma drained through a fistula of the duodenal bulb]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2010, Volume: 107, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Duodenal Diseases; Duodenal Neoplasms; Female; Gemcitabine; Humans; Intestinal Fistula; Liver Neoplasms; Neoplasm Invasiveness	2010
Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PloS one, 2010, Dec-16, Volume: 5, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Drug Design; Felodipine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-6; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Phenotype	2010
[A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Tegafur; Treatment Outcome	2010
[Two cases of curatively resected intrahepatic cholangiocellular carcinomas through effective response to neoadjuvant chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography Scanners, X-Ray Computed	2011
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. Journal of hepato-biliary-pancreatic sciences, 2011, Volume: 18, Issue:5 Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Cycle Proteins; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Real-Time Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Neoplasm	2011
Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma. Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension; Magnetic Resonance Imaging; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Posterior Leukoencephalopathy Syndrome; Prognosis; Seizures	2012
Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011, Volume: 99, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chi-Square Distribution; Cholangiocarcinoma; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Hepatic Duct, Common; Humans; Klatskin Tumor; Lymphatic Metastasis; Male; Middle Aged; Radiosurgery; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	2011
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. International journal of cancer, 2012, Aug-01, Volume: 131, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoembolization, Therapeutic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Survival Rate; Treatment Outcome	2012
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:11 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male	2011
Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Treatment Outcome	2012
[A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed	2011
[A case of adenosquamous carcinoma of lower extrahepatic bile duct]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:1 Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Staging; Remission Induction	2012
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors. Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Proportional Hazards Models; Tegafur	2012
Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:5 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Jaundice; Male; Middle Aged; Prognosis	2012
Prognostic significance of aquaporins in human biliary tract carcinoma. Oncology reports, 2012, Volume: 27, Issue:6 Topics: Aged; Aged, 80 and over; Aquaporin 1; Aquaporin 4; Aquaporin 5; Aquaporins; Bile Duct Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Tegafur	2012
Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. Chemotherapy, 2012, Volume: 58, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Retrospective Studies; Survival Analysis	2012
Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Annals of surgery, 2012, Volume: 256, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Hepatectomy; Humans; Immunohistochemistry; Male; Middle Aged; Pancreaticoduodenectomy; Prognosis; Survival Analysis	2012
Cholangiocarcinoma in a young woman with perinatally acquired HIV. Journal of pediatric gastroenterology and nutrition, 2013, Volume: 56, Issue:6 Topics: Adult; Antimetabolites, Antineoplastic; Antiretroviral Therapy, Highly Active; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; HIV Infections; Humans; Jaundice; Treatment Outcome; Young Adult	2013
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma. The Journal of surgical research, 2013, Volume: 181, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Proliferating Cell Nuclear Antigen; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
[A case of unresectable hilar cholangiocarcinoma successfully treated by gemcitabine and S-1 combination chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Stents; Tegafur	2012
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study. Journal of gastrointestinal and liver diseases : JGLD, 2012, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies	2012
Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Annals of surgical oncology, 2013, Volume: 20, Issue:1 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Carcinoma; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome	2013
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues. The oncologist, 2012, Volume: 17, Issue:12 Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; CA-125 Antigen; Capecitabine; Carcinoembryonic Antigen; Carrier Proteins; CDX2 Transcription Factor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cytokines; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Glycoproteins; Hepatectomy; Homeodomain Proteins; Humans; Immunohistochemistry; Keratin-20; Keratins; Liver; Liver Neoplasms; Lymph Node Excision; Magnetic Resonance Imaging; Membrane Transport Proteins; Phenotype; Portal Vein; Pregnancy; Receptors, Estrogen; Receptors, Progesterone	2012
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells. Anticancer research, 2012, Volume: 32, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays	2012
[Three cases of recurrent bile duct cancer diagnosed and treated by double-balloon endoscopy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Endoscopy; Female; Gemcitabine; Humans; Male; Middle Aged; Recurrence	2012
[Combination therapy for inoperable cholangiocellular carcinoma-systemic chemotherapy and hepatic arterial injection]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged	2012
[A case of advanced cholangiolocellular carcinoma successfully treated by neoadjuvant chemotherapy with gemcitabine followed by radical resection]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging	2012
[Long-term survival in 2 cases with unresectable hilar bile duct cancer and sclerosing cholangitis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangitis, Sclerosing; Deoxycytidine; Female; Gemcitabine; Humans; Male; Time Factors; Treatment Outcome	2012
Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation; Male; Middle Aged; Neoplasm Invasiveness; Postoperative Complications; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome	2013
Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Japanese journal of clinical oncology, 2004, Volume: 34, Issue:9 Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2004
Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2004, Volume: 180, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Palliative Care; Prevalence; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Survival Analysis; Survival Rate; Treatment Outcome	2004
[Is there a nonsurgical therapeutic approach to cholangiocellular carcinomas?]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2006, Volume: 77, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Brachytherapy; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholestasis; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hepatic Duct, Common; Humans; Jejunostomy; Neoadjuvant Therapy; Palliative Care; Photochemotherapy; Radiotherapy, Adjuvant; Stents; Survival Rate	2006
Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:5 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brain Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin	2006
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC cancer, 2006, Jul-17, Volume: 6 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Palliative Care; Quality of Life; Survival Analysis	2006
Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. Journal of cancer research and clinical oncology, 2006, Volume: 132, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2006
Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzothiazoles; Bile Duct Neoplasms; Cell Count; Cell Cycle; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Immunoblotting; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Receptors, Aryl Hydrocarbon; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Toluene	2006
[A case of stage IVA intrahepatic biliary tract cancer successfully treated with gemcitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:10 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Administration Routes; Floxuridine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Tomography, X-Ray Computed	2006
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. Journal of hepatology, 2007, Volume: 46, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Down-Regulation; Drug Interactions; Fluoresceins; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tannins	2007
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Middle Aged	2006
Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice. Annals of surgical oncology, 2007, Volume: 14, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Cell Proliferation; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2007
[Biliary tract carcinoma in elderly patients in whom gemcitabine chemotherapy induced complete remission - a report of two cases]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Remission Induction	2007
Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World journal of gastroenterology, 2007, May-28, Volume: 13, Issue:20 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Platelet Aggregation Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome	2007
Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2008, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Chemoembolization, Therapeutic; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Contraindications; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Hepatectomy; Hepatic Artery; Humans; Injections, Intra-Arterial; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2008
Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. European radiology, 2008, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Palliative Care; Treatment Outcome	2008
[National study of adjuvant treatments of resected cholangiocarcinoma]. Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:1 Pt. 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; France; Gemcitabine; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic	2008
Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. American journal of nephrology, 1999, Volume: 19, Issue:5 Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Needle; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Pancreatic Neoplasms; Renal Dialysis; Ribonucleotide Reductases	1999
Elevation of urinary porphyrin levels following gemcitabine administration. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Male; Porphyrins	1999